TelyRx Holdings (TELY) Q4 2025 earnings summary

Executive summary

• Revenue reached $42.9 million for the year ended December 31, 2025, up from $9.5 million in 2024, with Q4 2025 revenue at $14.3 million, up from $12.3 million in Q3 2025 and $4.6 million in Q4 2024.

• Prescriptions filled in Q4 2025 totaled 177,713, up from 149,857 in Q3 2025 and 53,390 in Q4 2024.

• The company operates a digital pharmacy platform, connecting patients with providers and delivering medications across 48 U.S. states and territories.

Financial highlights

• Year-over-year revenue growth was more than 350%, from $9.5 million in 2024 to $42.9 million in 2025.

• Q4 2025 revenue increased 16% sequentially from Q3 2025 and over 200% year-over-year from Q4 2024.

• Number of prescriptions filled in Q4 2025 grew 19% sequentially from Q3 2025 and over 230% year-over-year from Q4 2024.

Outlook and guidance

• Full financial results for Q1 2026 are scheduled for release in May 2026.

• Management highlights continued quarter-over-quarter revenue growth and expects ongoing expansion in the cash-pay prescription market.